Physician profile
Davis Young
NPI 1962912782
$4,811.99
in general payments reported to CMS, 2019-2025
14 companies · $658 in 2025
The $658 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,017 · 2022: $1,121 · 2023: $869 · 2024: $1,148 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,674.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,669.23 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,076.63 | 2021-2024 | |
| Novo Nordisk INC | $896.28 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $249.34 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.15 | 2022-2023 | Spiriva Respimat |
| Exact Sciences Corporation | $137.17 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $115.49 | 2021-2022 | |
| Lilly USA, LLC | $110.28 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $106.64 | 2021-2024 | Eliquis, Camzyos |
| Phathom Pharmaceuticals, INC. | $84.94 | 2024-2025 | Voquezna |
| Amgen INC. | $84.93 | 2022-2024 | Repatha, Otezla |
| Abbott Laboratories | $62.89 | 2022-2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $41.56 | 2022-2025 | Gardasil 9, Vaxelis, Capvaxive |
| Glaxosmithkline, LLC. | $25.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Davis Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.